Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Richez

Showing results (1-10 of 206) with videos related to

Pageof 21
Sort By:
La Revue Du Praticien|December 12, 2012
[Pathophysiology of rheumatoid arthritis]Thierry Lequerré, Christophe Richez
Expert Opinion on Drug Safety|December 3, 2010
Clinical safety of tocilizumab in rheumatoid arthritisBernard Bannwarth, Christophe Richez
Joint Bone Spine|July 17, 2009
The dextropropoxyphene controversyBernard Bannwarth, Christophe Richez
Expert Opinion on Pharmacotherapy|June 26, 2020
What value do JAK inhibitors have in treating rheumatoid arthritis?Christophe Richez, Marie-Elise Truchetet
Expert Opinion on Pharmacotherapy|August 17, 2021
Evaluating filgotinib for the treatment of rheumatoid arthritisChristophe Richez, Marie-Elise Truchetet
Annals of the Rheumatic Diseases|June 24, 2018
Response to: 'Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1' by Michot et al and 'Checkpoint inhibitor-associated immune arthritis' by Arnaud <i>et al</i>Marie Kostine, Christophe Richez, Thierry Schaeverbeke, et al.
Joint Bone Spine|April 2, 2017
Monitoring of Epstein-Barr virus (EBV)/cytomegalovirus (CMV)/varicella-zoster virus (VZV) load in patients receiving tocilizumab for rheumatoid arthritisMarc Scherlinger, Sophie Alain, Christophe Richez
The Journal of Rheumatology|April 1, 2005
Infliximab induced chilblain lupus in a patient with rheumatoid arthritisChristophe Richez, Chantal Dumoulin, Thierry Schaeverbeke
Joint Bone Spine|November 27, 2012
When and where does rheumatoid arthritis begin?Thierry Schaeverbeke, Marie-Élise Truchetet, Christophe Richez
Joint Bone Spine|June 29, 2013
Gut metagenome and spondyloarthritisThierry Schaeverbeke, Marie-Elise Truchetet, Christophe Richez
Pageof 21

Showing results (1-10 of 206) with videos related to

Sort By:
Pageof 21
La Revue Du Praticien|December 12, 2012
[Pathophysiology of rheumatoid arthritis]Thierry Lequerré, Christophe Richez
Expert Opinion on Drug Safety|December 3, 2010
Clinical safety of tocilizumab in rheumatoid arthritisBernard Bannwarth, Christophe Richez
Joint Bone Spine|July 17, 2009
The dextropropoxyphene controversyBernard Bannwarth, Christophe Richez
Expert Opinion on Pharmacotherapy|June 26, 2020
What value do JAK inhibitors have in treating rheumatoid arthritis?Christophe Richez, Marie-Elise Truchetet
Expert Opinion on Pharmacotherapy|August 17, 2021
Evaluating filgotinib for the treatment of rheumatoid arthritisChristophe Richez, Marie-Elise Truchetet
Annals of the Rheumatic Diseases|June 24, 2018
Response to: 'Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1' by Michot et al and 'Checkpoint inhibitor-associated immune arthritis' by Arnaud <i>et al</i>Marie Kostine, Christophe Richez, Thierry Schaeverbeke, et al.
Joint Bone Spine|April 2, 2017
Monitoring of Epstein-Barr virus (EBV)/cytomegalovirus (CMV)/varicella-zoster virus (VZV) load in patients receiving tocilizumab for rheumatoid arthritisMarc Scherlinger, Sophie Alain, Christophe Richez
The Journal of Rheumatology|April 1, 2005
Infliximab induced chilblain lupus in a patient with rheumatoid arthritisChristophe Richez, Chantal Dumoulin, Thierry Schaeverbeke
Joint Bone Spine|November 27, 2012
When and where does rheumatoid arthritis begin?Thierry Schaeverbeke, Marie-Élise Truchetet, Christophe Richez
Joint Bone Spine|June 29, 2013
Gut metagenome and spondyloarthritisThierry Schaeverbeke, Marie-Elise Truchetet, Christophe Richez
Pageof 21